The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.

The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.

The present invention relates to compounds of formula (I)

##STR00001##

or a pharmaceutically acceptable salt form thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of disease.

The present invention relates to compounds of formula (I)

##STR00001##

or a pharmaceutically acceptable salt form thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of disease.

Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

The present disclosure provides heteroaryl compounds of Formula I, processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to the programmed necrosis pathway. Formula I is:

##STR00001##

The present disclosure provides heteroaryl compounds of Formula I, processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to the programmed necrosis pathway. Formula I is:

##STR00001##

The disclosure provides novel solid state forms of Compound I chosen from Compound I Phosphate Salt Hydrate Form A, Compound I free form Monohydrate, Compound I Phosphate Salt Methanol Solvate, and Compound I Phosphate Salt MEK Solvate, compositions comprising the same, and methods of making and using the same, including uses in treating APOL1 mediated disease (such as, e.g., APOL1 mediated kidney disease). Also provided herein are novel solid state forms of Compound II chosen from Compound II Phosphate Salt Hemihydrate Form A, Compound II free form Hemihydrate Form A, and Compound II free form Form C, compositions comprising the same, and methods of making and using the same, including uses in treating APOL1 mediated disease (such as, e.g., APOL1 mediated kidney disease).

The disclosure provides novel solid state forms of Compound I chosen from Compound I Phosphate Salt Hydrate Form A, Compound I free form Monohydrate, Compound I Phosphate Salt Methanol Solvate, and Compound I Phosphate Salt MEK Solvate, compositions comprising the same, and methods of making and using the same, including uses in treating APOL1 mediated disease (such as, e.g., APOL1 mediated kidney disease). Also provided herein are novel solid state forms of Compound II chosen from Compound II Phosphate Salt Hemihydrate Form A, Compound II free form Hemihydrate Form A, and Compound II free form Form C, compositions comprising the same, and methods of making and using the same, including uses in treating APOL1 mediated disease (such as, e.g., APOL1 mediated kidney disease).